CD8A and neoplasm: In the B16F10 cell line, treatment with the modified liposomes resulted in a notable reduction in M2-TAMs and CD4+Foxp3+ T cells, along with an increase in M1-TAMs, CD8+ T cells, and T cell activity, resulting in the enhancement of the tumor inhibition rate